FoxO1, the transcriptional chief of staff of energy metabolism

Bone

Volumn 50, Issue 2, 2012, Pages 437-443

  Kousteni, Stavroula ^a  

^a College of Physicians and Surgeons Columbia University ^*  (United States)

Author keywords

Adipose tissue; Energy homeostasis; FoxO1; Glucose metabolism; Liver; Muscle; Osteoblasts; Pancreas; Skeleton

Indexed keywords

TRANSCRIPTION FACTOR FKHR;

B LYMPHOCYTE; CELL MIGRATION; CELL SURVIVAL; DYSLIPIDEMIA; ENERGY EXPENDITURE; ENERGY METABOLISM; ENERGY RESOURCE; GLUCONEOGENESIS; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HOMEOSTASIS; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; METABOLIC DISORDER; METABOLIC REGULATION; MUSCLE ATROPHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSTEOBLAST; PANCREAS; PROTEIN FUNCTION; REVIEW; SKELETAL MUSCLE; TRANSCRIPTION INITIATION;

ANIMALS; ENERGY METABOLISM; FORKHEAD TRANSCRIPTION FACTORS; GLUCOSE; HUMANS; METABOLIC DISEASES; ORGAN SPECIFICITY; TRANSCRIPTION, GENETIC;

EID: 84855868834     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2011.06.034     Document Type: Review

References (77)

1. Lee N.K., Sowa H., Hinoi E., Ferron M., Ahn J.D., Confavreux C., et al. Endocrine regulation of energy metabolism by the skeleton. Cell 2007, 130:456-469.
2. Fulzele K., Riddle R.C., Digirolamo D.J., Cao X., Wan C., Chen D., et al. Insulin receptor signaling in osteoblasts regulates postnatal bone acquisition and body composition. Cell 2010, 142:309-319.
3. Yoshikawa Y., Kode A., Xu L., Mosialou I., Silva B.C., Ferron M., et al. Genetic evidence points to an osteocalcin-independent influence of osteoblasts on energy metabolism. J Bone Miner Res 2011, 26:2012-2025.
4. Ferron M., Wei J., Yoshizawa T., Del F.A., DePinho R.A., Teti A., et al. Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell 2010, 142:296-308.
5. Yoshizawa T., Hinoii E., Jung D.Y., Kajimura D., Ferron M., Seo J., et al. The transcription factor ATF4 regulates glucose metabolism through its expression in osteoblasts. J Clin Invest 2009, 119.
6. Rached M.T., Kode A., Silva B.C., Jung D.Y., Gray S., Ong H., et al. FoxO1 expression in osteoblasts regulates glucose homeostasis through regulation of osteocalcin in mice. J Clin Invest 2010, 120:357-368.
7. Pittas A.G., Harris S.S., Eliades M., Stark P., wson-Hughes B. Association between serum osteocalcin and markers of metabolic phenotype. J Clin Endocrinol Metab 2009, 94:827-832.
8. Kindblom J.M., Ohlsson C., Ljunggren O., Karlsson M.K., Tivesten A., Smith U., et al. Plasma osteocalcin is inversely related to fat mass and plasma glucose in elderly Swedish men. J Bone Miner Res 2009, 24:785-791.
9. Kanazawa I., Yamaguchi T., Yamamoto M., Yamauchi M., Kurioka S., Yano S., et al. Serum osteocalcin level is associated with glucose metabolism and atherosclerosis parameters in type 2 diabetes mellitus. J Clin Endocrinol Metab 2009, 94:45-49.
10. Saleem U., Mosley T.H., Kullo I.J. Serum osteocalcin is associated with measures of insulin resistance, adipokine levels, and the presence of metabolic syndrome. Arterioscler Thromb Vasc Biol 2010, 30:1474-1478.
11. van der H.A., Burgering B.M. Stressing the role of FoxO proteins in lifespan and disease. Nat Rev Mol Cell Biol 2007, 8:440-450.
12. Jacobs F.M., van der Heide L.P., Wijchers P.J., Burbach J.P., Hoekman M.F., Smidt M.P. FoxO6, a novel member of the FoxO class of transcription factors with distinct shuttling dynamics. J Biol Chem 2003, 278:35959-35967.
13. Paik J.H., Kollipara R., Chu G., Ji H., Xiao Y., Ding Z., et al. FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell 2007, 128:309-323.
14. Arden K.C. FOXO animal models reveal a variety of diverse roles for FOXO transcription factors. Oncogene 2008, 27:2345-2350.
15. Hosaka T., Biggs W.H., Tieu D., Boyer A.D., Varki N.M., Cavenee W.K., et al. Disruption of forkhead transcription factor (FOXO) family members in mice reveals their functional diversification. Proc Natl Acad Sci U S A 2004, 101:2975-2980.
16. Bastie C.C., Nahle Z., McLoughlin T., Esser K., Zhang W., Unterman T., et al. FoxO1 stimulates fatty acid uptake and oxidation in muscle cells through CD36-dependent and -independent mechanisms. J Biol Chem 2005, 280:14222-14229.
17. Dong X.C., Copps K.D., Guo S., Li Y., Kollipara R., DePinho R.A., et al. Inactivation of hepatic Foxo1 by insulin signaling is required for adaptive nutrient homeostasis and endocrine growth regulation. Cell Metab 2008, 8:65-76.
18. Kitamura T., Nakae J., Kitamura Y., Kido Y., Biggs W.H., Wright C.V., et al. The forkhead transcription factor Foxo1 links insulin signaling to Pdx1 regulation of pancreatic beta cell growth. J Clin Invest 2002, 110:1839-1847.
19. Nakae J., Biggs W.H., Kitamura T., Cavenee W.K., Wright C.V., Arden K.C., et al. Regulation of insulin action and pancreatic beta-cell function by mutated alleles of the gene encoding forkhead transcription factor Foxo1. Nat Genet 2002, 32:245-253.
20. Buteau J., Spatz M.L., Accili D. Transcription factor FoxO1 mediates glucagon-like peptide-1 effects on pancreatic beta-cell mass. Diabetes 2006, 55:1190-1196.
21. Kitamura T., Feng Y., Kitamura Y.I., Chua S.C., Xu A.W., Barsh G.S., et al. Forkhead protein FoxO1 mediates Agrp-dependent effects of leptin on food intake. Nat Med 2006, 12:534-540.
22. Cherrington A.D. Banting lecture 1997. Control of glucose uptake and release by the liver in vivo. Diabetes 1999, 48:1198-1214.
23. Ahlgren U., Jonsson J., Jonsson L., Simu K., Edlund H. Beta-cell-specific inactivation of the mouse Ipf1/Pdx1 gene results in loss of the beta-cell phenotype and maturity onset diabetes. Genes Dev 1998, 12:1763-1768.
24. Al-Masri M., Krishnamurthy M., Li J., Fellows G.F., Dong H.H., Goodyer C.G., et al. Effect of forkhead box O1 (FOXO1) on beta cell development in the human fetal pancreas. Diabetologia 2010, 53:699-711.
25. Kitamura T., Kitamura Y.I., Kobayashi M., Kikuchi O., Sasaki T., DePinho R.A., et al. Regulation of pancreatic juxtaductal endocrine cell formation by FoxO1. Mol Cell Biol 2009, 29:4417-4430.
26. Kitamura Y.I., Kitamura T., Kruse J.P., Raum J.C., Stein R., Gu W., et al. FoxO1 protects against pancreatic beta cell failure through NeuroD and MafA induction. Cell Metab 2005, 2:153-163.
27. Hashimoto N., Kido Y., Uchida T., Asahara S., Shigeyama Y., Matsuda T., et al. Ablation of PDK1 in pancreatic beta cells induces diabetes as a result of loss of beta cell mass. Nat Genet 2006, 38:589-593.
28. Dickson L.M., Rhodes C.J. Pancreatic beta-cell growth and survival in the onset of type 2 diabetes: a role for protein kinase B in the Akt?. Am J Physiol Endocrinol Metab 2004, 287:E192-E198.
29. Ai J., Duan J., Lv X., Chen M., Yang Q., Sun H., et al. Overexpression of FoxO1 causes proliferation of cultured pancreatic beta cells exposed to low nutrition. Biochemistry 2010, 49:218-225.
30. Bell G.I., Polonsky K.S. Diabetes mellitus and genetically programmed defects in beta-cell function. Nature 2001, 414:788-791.
31. Robertson R.P., Harmon J., Tran P.O., Tanaka Y., Takahashi H. Glucose toxicity in beta-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes 2003, 52:581-587.
32. Kawamori D., Kaneto H., Nakatani Y., Matsuoka T.A., Matsuhisa M., Hori M., et al. The forkhead transcription factor Foxo1 bridges the JNK pathway and the transcription factor PDX-1 through its intracellular translocation. J Biol Chem 2006, 281:1091-1098.
33. Nakae J., Kitamura T., Silver D.L., Accili D. The forkhead transcription factor Foxo1 (Fkhr) confers insulin sensitivity onto glucose-6-phosphatase expression. J Clin Invest 2001, 108:1359-1367.
34. Altomonte J., Richter A., Harbaran S., Suriawinata J., Nakae J., Thung S.N., et al. Inhibition of Foxo1 function is associated with improved fasting glycemia in diabetic mice. Am J Physiol Endocrinol Metab 2003, 285:E718-E728.
35. Nakae J., Park B.C., Accili D. Insulin stimulates phosphorylation of the forkhead transcription factor FKHR on serine 253 through a Wortmannin-sensitive pathway. J Biol Chem 1999, 274:15982-15985.
36. Matsumoto M., Pocai A., Rossetti L., DePinho R.A., Accili D. Impaired regulation of hepatic glucose production in mice lacking the forkhead transcription factor Foxo1 in liver. Cell Metab 2007, 6:208-216.
37. Liu Y., Dentin R., Chen D., Hedrick S., Ravnskjaer K., Schenk S., et al. A fasting inducible switch modulates gluconeogenesis via activator/coactivator exchange. Nature 2008, 456:269-273.
38. Haeusler R.A., Kaestner K.H., Accili D. FoxOs function synergistically to promote glucose production. J Biol Chem 2010, 285:35245-35248.
39. Nathan D.M., Cleary P.A., Backlund J.Y., Genuth S.M., Lachin J.M., Orchard T.J., et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005, 353:2643-2653.
40. Savage D.B., Petersen K.F., Shulman G.I. Disordered lipid metabolism and the pathogenesis of insulin resistance. Physiol Rev 2007, 87:507-520.
41. Altomonte J., Cong L., Harbaran S., Richter A., Xu J., Meseck M., et al. Foxo1 mediates insulin action on apoC-III and triglyceride metabolism. J Clin Invest 2004, 114:1493-1503.
42. Matsumoto M., Han S., Kitamura T., Accili D. Dual role of transcription factor FoxO1 in controlling hepatic insulin sensitivity and lipid metabolism. J Clin Invest 2006, 116:2464-2472.
43. Kamagate A., Qu S., Perdomo G., Su D., Kim D.H., Slusher S., et al. FoxO1 mediates insulin-dependent regulation of hepatic VLDL production in mice. J Clin Invest 2008, 118:2347-2364.
44. Haeusler R.A., Han S., Accili D. Hepatic FoxO1 ablation exacerbates lipid abnormalities during hyperglycemia. J Biol Chem 2010, 285:26861-26868.
45. Inagaki T., Dutchak P., Zhao G., Ding X., Gautron L., Parameswara V., et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab 2007, 5:415-425.
46. de L.P., Moreno M., Silvestri E., Lombardi A., Goglia F., Lanni A. Fuel economy in food-deprived skeletal muscle: signaling pathways and regulatory mechanisms. FASEB J 2007, 21:3431-3441.
47. Schiaffino S., Reggiani C. Molecular diversity of myofibrillar proteins: gene regulation and functional significance. Physiol Rev 1996, 76:371-423.
48. Nishiyama T., Kii I., Kudo A. Inactivation of Rho/ROCK signaling is crucial for the nuclear accumulation of FKHR and myoblast fusion. J Biol Chem 2004, 279:47311-47319.
49. Furuyama T., Kitayama K., Yamashita H., Mori N. Forkhead transcription factor FOXO1 (FKHR)-dependent induction of PDK4 gene expression in skeletal muscle during energy deprivation. Biochem J 2003, 375:365-371.
50. Kamei Y., Miura S., Suzuki M., Kai Y., Mizukami J., Taniguchi T., et al. Skeletal muscle FOXO1 (FKHR) transgenic mice have less skeletal muscle mass, down-regulated Type I (slow twitch/red muscle) fiber genes, and impaired glycemic control. J Biol Chem 2004, 279:41114-41123.
51. Kitamura T., Kitamura Y.I., Funahashi Y., Shawber C.J., Castrillon D.H., Kollipara R., et al. A Foxo/Notch pathway controls myogenic differentiation and fiber type specification. J Clin Invest 2007, 117:2477-2485.
52. Southgate R.J., Neill B., Prelovsek O., El-Osta A., Kamei Y., Miura S., et al. FOXO1 regulates the expression of 4E-BP1 and inhibits mTOR signaling in mammalian skeletal muscle. J Biol Chem 2007, 282:21176-21186.
53. Sandri M., Sandri C., Gilbert A., Skurk C., Calabria E., Picard A., et al. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 2004, 117:399-412.
54. Allen D.L., Unterman T.G. Regulation of myostatin expression and myoblast differentiation by FoxO and SMAD transcription factors. Am J Physiol Cell Physiol 2007, 292:C188-C199.
55. Leger B., Vergani L., Soraru G., Hespel P., Derave W., Gobelet C., et al. Human skeletal muscle atrophy in amyotrophic lateral sclerosis reveals a reduction in Akt and an increase in atrogin-1. FASEB J 2006, 20:583-585.
56. Leger B., Cartoni R., Praz M., Lamon S., Deriaz O., Crettenand A., et al. Akt signalling through GSK-3beta, mTOR and Foxo1 is involved in human skeletal muscle hypertrophy and atrophy. J Physiol 2006, 576:923-933.
57. Large V., Peroni O., Letexier D., Ray H., Beylot M. Metabolism of lipids in human white adipocyte. Diabetes Metab 2004, 30:294-309.
58. Despres J.P., Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006, 444:881-887.
59. Qiao L., Shao J. SIRT1 regulates adiponectin gene expression through Foxo1-C/enhancer-binding protein alpha transcriptional complex. J Biol Chem 2006, 281:39915-39924.
60. Nakae J., Cao Y., Oki M., Orba Y., Sawa H., Kiyonari H., et al. Forkhead transcription factor FoxO1 in adipose tissue regulates energy storage and expenditure. Diabetes 2008, 57:563-576.
61. Nakae J., Kitamura T., Kitamura Y., Biggs W.H., Arden K.C., Accili D. The forkhead transcription factor Foxo1 regulates adipocyte differentiation. Dev Cell 2003, 4:119-129.
62. Accili D., Taylor S.I. Targeted inactivation of the insulin receptor gene in mouse 3T3-L1 fibroblasts via homologous recombination. Proc Natl Acad Sci U S A 1991, 88:4708-4712.
63. Miki H., Yamauchi T., Suzuki R., Komeda K., Tsuchida A., Kubota N., et al. Essential role of insulin receptor substrate 1 (IRS-1) and IRS-2 in adipocyte differentiation. Mol Cell Biol 2001, 21:2521-2532.
64. Tseng Y.H., Kriauciunas K.M., Kokkotou E., Kahn C.R. Differential roles of insulin receptor substrates in brown adipocyte differentiation. Mol Cell Biol 2004, 24:1918-1929.
65. Jing E., Gesta S., Kahn C.R. SIRT2 regulates adipocyte differentiation through FoxO1 acetylation/deacetylation. Cell Metab 2007, 6:105-114.
66. Armoni M., Harel C., Karni S., Chen H., Bar-Yoseph F., Ver M.R., et al. FOXO1 represses peroxisome proliferator-activated receptor-gamma1 and -gamma2 gene promoters in primary adipocytes. A novel paradigm to increase insulin sensitivity. J Biol Chem 2006, 281:19881-19891.
67. Narkar V.A., Downes M., Yu R.T., Embler E., Wang Y.X., Banayo E., et al. AMPK and PPARdelta agonists are exercise mimetics. Cell 2008, 134:405-415.
68. Kim J.R., Jung H.S., Bae S.W., Kim J.H., Park B.L., Choi Y.H., et al. Polymorphisms in FOXO gene family and association analysis with BMI. Obesity (Silver, Spring) 2006, 14:188-193.
69. Kuningas M., Magi R., Westendorp R.G., Slagboom P.E., Remm M., van H.D. Haplotypes in the human Foxo1a and Foxo3a genes; impact on disease and mortality at old age. Eur J Hum Genet 2007, 15:294-301.
70. Karim M.A., Craig R.L., Wang X., Hale T.C., Elbein S.C. Analysis of FOXO1A as a candidate gene for type 2 diabetes. Mol Genet Metab 2006, 88:171-177.
71. Marchetti V., Menghini R., Rizza S., Vivanti A., Feccia T., Lauro D., et al. Benfotiamine counteracts glucose toxicity effects on endothelial progenitor cell differentiation via Akt/FoxO signaling. Diabetes 2006, 55:2231-2237.
72. Bottcher Y., Tonjes A., Enigk B., Scholz G.H., Bluher M., Stumvoll M., et al. A SNP haplotype of the forkhead transcription factor FOXO1A gene may have a protective effect against type 2 diabetes in German Caucasians. Diabetes Metab 2007, 33:277-283.
73. Mussig K., Staiger H., Machicao F., Stancakova A., Kuusisto J., Laakso M., et al. Association of common genetic variation in the FOXO1 gene with beta-cell dysfunction, impaired glucose tolerance, and type 2 diabetes. J Clin Endocrinol Metab 2009, 94:1353-1360.
74. Maiese K., Morhan S.D., Chong Z.Z. Oxidative stress biology and cell injury during type 1 and type 2 diabetes mellitus. Curr Neurovasc Res 2007, 4:63-71.
75. Zhou M., Ma X., Li H., Pan X., Tang J., Gao Y., et al. Serum osteocalcin concentrations in relation to glucose and lipid metabolism in Chinese individuals. Eur J Endocrinol 2009, 161:723-729.
76. Bao Y.Q., Zhou M., Zhou J., Lu W., Gao Y.C., Pan X.P., et al. Relationship between serum osteocalcin and glycaemic variability in Type 2 diabetes. Clin Exp Pharmacol Physiol 2011, 38:50-54.
77. Reinehr T., Roth C.L. A new link between skeleton, obesity and insulin resistance: relationships between osteocalcin, leptin and insulin resistance in obese children before and after weight loss. Int J Obes (Lond) 2010, 34:852-858.